Certuity’s Lyell Immunopharma LYEL Stock Holding History

Certuity’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-750	Closed	-$110K	–	226
2022 Q3	$110K	Buy	+750	New	+$102K	0.03%	187

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Certuity's LYEL Position: Q4 2022 in Review

Certuity sold out of Lyell Immunopharma (LYEL) in Q4 2022, closing a stake of 750 shares — an estimated $110K sold.

Certuity first reported a position in LYEL in Q3 2022 and held it in 1 quarter. The position peaked at $110K in Q3 2022. 93 funds tracked by Wall St. Rank hold LYEL as of Q4 2022.

Certuity reported no remaining Lyell Immunopharma position as of Q4 2022 after selling out during the quarter.
Certuity sold 750 Lyell Immunopharma shares in Q4 2022, an estimated $110K.
Certuity first reported a position in Lyell Immunopharma in Q3 2022 and held it in 1 quarter.
Certuity's Lyell Immunopharma position peaked at $110K in Q3 2022.
93 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2022.

Based on Certuity's 13F filing for Q4 2022, filed 13 Feb 2023.